About US
Contact us
-
GSK manufacturing review prompts Scynexis to pull Brexafemme, halt trials over contamination concernsWhen Scynexis won FDA approval for itsantifungal drug ibrexafungerp back in 2021, some analystspredictedthe drug could eventually surpass the $1 billion annual sales threshold. But now the drug's lau2023/10/19
-
Mission: Possible: Big Pharmas back star-fronted lung cancer awareness pushA who’s who of biopharma companies havebackeda push to raise awareness about lung cancer among Hispanic and Latino Americans, funding a project that has enlisted a Mission: Impossible star to educate2023/10/17
-
Novartis targets first-line use for radiotherapy Lutathera after trial win in neuroendocrine tumorsMore than five years after an initial FDA approval, Novartis is touting positive trial results for its radiotherapy Lutathera as a first-line therapy against the rare cancer that killed Apple co-foun2023/10/17
-
Seagen and Astellas' Padcev, in Keytruda combo, delivers 'practice-changing' bladder cancer winAs Seagen prepares for its takeover by Pfizer, the company’s Astellas-partneredcancer drug Padcev has chalked up a key trial win—in combination with Merck's Keytruda—in previously untreated metastati2023/10/13
-
Look out, AZ. Lilly and Boehringer's Jardiance is ready to roll in chronic kidney disease after FDA nodFast on the heels of winning a European approval to treat chronic kidney disease (CKD), Eli Lilly and Boehringer Ingelheim's versatile SGLT2 inhibitor Jardiance is expanding its reach in the U.S., to2023/10/13
-
Merck and Eisai's Keytruda-Lenvima combo chalks up 2 more losses, this time in non-small cell lung cancerMerck and Eisai’s Keytruda-Lenvima tag team can’t seem to catch a break. Following a series of trial shortfalls this year in melanoma, colorectal cancer and head and neck squamous cell carcinoma, the2023/10/9
-
After FDA rejection, Lilly's ulcerative colitis drug Omvoh picks up support from England's NICEEven after Eli Lilly missed its first swing at the lucrative U.S. market with ulcerative colitis drug mirikizumab, the company’s launch is gaining steam overseas. Friday, England’s National Institute2023/10/9
-
Novartis makes sculptures to shape knowledge of cancer symptomsNovartis hasenlistedartists to help raise awareness of rare blood cancers, commissioning sculptures that portray the 10 key symptoms of the conditions to create a temporary exhibition that will tour2023/9/25
-
After FDA setback, PTC Therapeutics' DMD drug Translarna faces possible market withdrawal in EuropeA “surprised and extremely disappointed” PTC Therapeutics is scrambling to keep its Duchenne muscular dystrophy therapy Translarna on the European market after a detrimental review. The Committee for2023/9/25
-
Amgen, AstraZeneca focus on asthmatic punk rocker to show how Tezspire can unleash lust for lifeAmgen and AstraZeneca are returning to the TV party to show how Tezspire can help punks with a lust for life rise above their asthma symptoms and take complete control of their lives. The new TV spot2023/9/22